Company Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
The company’s earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes.
In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers.
DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.
| Country | France |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 105 |
| CEO | Daniel Tassé |
Contact Details
Address: 177-181 Avenue Pierre Brossolette Montrouge, 92120 France | |
| Phone | 33 1 55 42 78 78 |
| Website | dbv-technologies.com |
Stock Details
| Ticker Symbol | DBVT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001613780 |
| CUSIP Number | 23306J101 |
| ISIN Number | US23306J1016 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Daniel Tassé | Chief Executive Officer and Director |
| Virginie Simone Jeanine Verrechia Boucinha M.B.A. | Chief Financial Officer and Principal Accounting Officer |
| Dr. Pharis Mohideen | Chief Medical Officer |
| Dr. Kevin P. Malobisky M.S., Ph.D., R.A.C. | Chief Operations Officer |
| Katie Matthews | Investor Relations Officer |
| Michele F. Robertson | Chief Legal Officer |
| Caroline Daniere | Chief Human Resources Officer and Chief of Staff |
| Dr. Wence Agbotounou | Chief Clinical Trial Officer and Senior Vice President |
| Edward P. Jordan M.B.A. | Senior Vice President of Commercial Operations North America |
| Alan Kerr | Senior Vice President and Head of Global Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 22, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Jul 30, 2024 | 8-K | Current Report |
| Jul 30, 2024 | 10-Q | Quarterly Report |
| Jul 2, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 18, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 17, 2024 | F-6 POS | Post-effective amendments for immediately effective filing |
| May 17, 2024 | 8-K | Current Report |
| May 16, 2024 | 8-K | Current Report |